The immuno-oncology company Immunocore Ltd has recruited Bahija Jallal as its new chief executive to succeed Andrew Hotchkiss, the interim CEO, as its lead product for melanoma undergoes pivotal clinical studies. Dr Jallal comes from MedImmune, the biologics arm of AstraZeneca Plc, where she was president. At AstraZeneca, she oversaw the development of several new medicines, including Imfinzi, a checkpoint antibody for the treatment of bladder and lung cancers. She holds more than 15 patents and is a member of the Board of Trustees of the Johns Hopkins University in Baltimore, US.
Immunocore announced the appointment on 4 January 2018.
Copyright 2019 Evernow Publishing Ltd